Key clinical point: Refined software design and programming led to a low inappropriate-shock rate in implantable cardiac defibrillator patients with poor heart function.
Major finding: Freedom from inappropriate shocks at 18 months was 95.9%, significantly surpassing the 91.6% performance goal.
Study details: UNTOUCHED, a single-arm, multicenter study with 1,111 evaluable patients.
Disclosures: UNTOUCHED was sponsored by Boston Scientific, the company that markets the tested subcutaneous implantable cardioverter defibrillator. Dr. Gold has been a consultant to Boston Scientific and Medtronic and has been an investigator for trials sponsored by each of these companies.
FROM HEART RHYTHM 2020